BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-237@pharmaconomics
DTSTAMP:20260707T050246Z
DTSTART;VALUE=DATE:20260327
DTEND;VALUE=DATE:20260328
SUMMARY:BBIO PDUFA — BBP-418
DESCRIPTION:The FDA's approval decision on BBP-418 for limb-girdle muscular dystrophy type 2I/R9 is due Mar 27\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1743881/000114036126011991/ef20069329_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/237
URL:https://www.pharmaconomics.com/e/237
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BBIO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR